The latest market report published by Credence Research, Inc. “Global Alzheimer’s Therapeutics Market – Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2016 – 2022,” the Alzheimer’s therapeutics market was valued at USD 8,524.9 Mn in 2015, and is expected to reach USD 14,856.3 Mn by 2022, expanding at a CAGR of 8.02% from 2016 to 2022.
The purpose of the report is to illustrate the state of the market of Alzheimer’s Therapeutics, to present actual information about the volumes of production, exports, imports, consumption and the state of the market, the changes that took place in 2017, and also, to build a forecast for the growth of the industry in the medium term until 2026.
Browse here for full report: https://www.credenceresearch.com/report/alzeimers-therapeutic-market
Alzheimer’s disease is a progressive and currently incurable disease, and potential or supportive treatments have only emerged in the last decade. However, the currently available treatments are lacking in terms of efficacy or target-specificity. There are two types of drug classes used in treatment of Alzheimer’s disease, acetylcholinesterase (ACE) inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonist. ACE inhibitors constitute of galantamine hydrochloride, donepezil hydrochloride and rivastigmine; NMDA receptor antagonist includes mematidine hydrochloride. Since the discovery of what plaques and tangles comprised in Alzheimer’s – amyloid β (Aβ) peptide and hyperphosphorylated tau (p-tau) protein respectively. An immense research and development has been carried out to develop therapeutics which can limit the rate of synthesis, reduce the toxicity or clear these factors from the brain. However, these attempts have been largely unsuccessful. Hence, considering the continuously rising Alzheimer prevalent population, as well as limited drugs available for treatment, Alzheimer’s disease presents a lucrative opportunity for an effective disease-modifying therapy to enter the market.
The phase III drugs included in the pipeline analysis are ENA713 (Novartis Pharmaceuticals), Flutemetamol (18F) (GE Healthcare), LY450139 (Eli Lilly and Company), Dimebon (Medivation, Inc. & Pfizer, Inc.), and Aripiprazole/ BMS-337039 (Otsuka Pharmaceutical, Inc.). The overall pipeline for Alzeihmer’s is still very much dominated by small molecule drugs. However, there is still a considerable number of biologics in the pipeline with total 86 molecules, represented across all stages of development. According to market experts, the diversity of the several molecule types in the biologic group shows a certain level of innovation, with newer avenues being explored in accounts of recent failures. Overall, late stage clinical trials have highlighted very few molecules that could potentially replace current treatments during the forecast period.
Why was the report written?
This report is the result of an extensive survey drawn from Credence Research’s exclusive panel of leading global market industry executives; it provides data and analysis on buyer investment, acquisition, and developments within the global market research. It includes key topics such as global Alzheimer’s Therapeutics buyer expenditure and procurement behaviors and strategies and recognizes the threats and possibilities within the industry, economic outlook trends, and business confidence within global industry executives. Most secondary research reports are based on general industry drivers and do not understand the industry executives’ attitude and changing behaviors, creating a gap in presenting the business outlook of the industry; in an effort to bridge this gap, Credence Research created this primary research-based report by gathering the opinions of multiple stakeholders in the value chain of the global industry.
What is the current market landscape and what is changing?
Executives from the global industry anticipate an increase in levels of consolidation, with 55% of respondents projecting an increase in merger and acquisition (M&A) activities in 2017.
The report on the market of Alzheimer’s Therapeutics contains:
Analysis and forecast of Alzheimer’s Therapeutics market dynamics;
Analysis of domestic production, market shares of the main market players;
Analysis of exports and imports;
Analysis of factors, leading the development of the Alzheimer’s Therapeutics market;
Assessment and forecast of Alzheimer’s Therapeutics market development;
Financial and business profiles of the leading companies in the Alzheimer’s Therapeutics industry.
– Up to date working Alzheimer’s Therapeutics data by major regions in the world, the forecast of planned capacity additions by 2026
– The annual breakdown of capital expenditure spending on proposed Alzheimer’s Therapeutics for the period 2018 to 2026
– Planned Alzheimer’s Therapeutics additions and capital expenditure spending by key countries and companies across the world
– Planned capital expenditure spending on new Alzheimer’s Therapeutics projects by region, key countries, and companies
– Details of major planned Alzheimer’s Therapeutics projects in the world up to 2026
Also you can request us for sample in pdf with more details and graph: https://www.credenceresearch.com/sample-request/57811
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Credence Research Inc.
105 N 1st ST #429
Toll Free (US/CANADA): +1-800-361-8290